Eric Fink Net Worth

The estimated Net Worth of Eric Fink is at least $796 Thousand dollars as of 10 May 2021. Mr. Fink owns over 500 units of Global Blood Therapeutics stock worth over $353,477 and over the last 5 years he sold GBT stock worth over $442,767. In addition, he makes $0 as Chief Human Resource Officer at Global Blood Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Fink GBT stock SEC Form 4 insiders trading

Eric has made over 7 trades of the Global Blood Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 500 units of GBT stock worth $18,980 on 10 May 2021.

The largest trade he's ever made was exercising 6,250 units of Global Blood Therapeutics stock on 1 September 2020 worth over $428,063. On average, Eric trades about 2,290 units every 28 days since 2019. As of 10 May 2021 he still owns at least 5,161 units of Global Blood Therapeutics stock.

You can see the complete history of Mr. Fink stock trades at the bottom of the page.

Eric Fink biography

Eric Fink serves as Chief Human Resource Officer of the Company. Prior to joining us, from 2010 until July 2019, he most recently served as Vice President, Human Resources, at Jazz Pharmaceuticals, a global biopharmaceutical company. While there, he held a variety of human resource senior leadership positions to develop human capital and organizational development strategies and scale the global HR operating model to better serve the expanding business. From 2008 to 2009, he held a leadership position in the sales training organization at Bayer Healthcare, a multinational pharmaceutical and life sciences company. From 1999 to 2008, he held various roles at GlaxoSmithKline, a global healthcare company, across a wide spectrum of the U.S. commercial function, including Sales, Sales Training, Commercial Analytics, and Sales Management. He received a B.S. in Biology from Pennsylvania State University and an M.S. in Organizational Leadership from Mercyhurst University.

How old is Eric Fink?

Eric Fink is 43, he's been the Chief Human Resource Officer of Global Blood Therapeutics since 2019. There are 21 older and no younger executives at Global Blood Therapeutics. The oldest executive at Global Blood Therapeutics Inc. is Willie Brown, 86, who is the Independent Director.

What's Eric Fink's mailing address?

Eric's mailing address filed with the SEC is C/O GLOBAL BLOOD THERAPEUTICS, INC., 181 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Global Blood Therapeutics

Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third..., and Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.

What does Global Blood Therapeutics do?

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.

Complete history of Mr. Fink stock trades at Global Blood Therapeutics

Global Blood Therapeutics executives and stock owners

Global Blood Therapeutics executives and other stock owners filed with the SEC include:

• Ted Love,
  President, Chief Executive Officer, Director
• Brian Cathers,
  Chief Scientific Officer
• Tricia Suvari,
  Chief Legal Officer
• Jung Choi,
  Chief Business and Strategy Officer
• David Johnson,
  Chief Commercial Officer
• Jeffrey Farrow,
  Chief Financial Officer
• Dr. Ted W. Love,
  Pres, CEO & Director
• Dr. Ted W. Love M.D.,
  Pres, CEO & Director
• David L. Johnson,
  Chief Commercial Officer
• Jeffrey S. Farrow,
  CFO & Principal Accounting Officer
• Jung E. Choi,
  Chief Bus. & Strategy Officer
• Dr. Kim Smith-Whitley M.D.,
  Exec. VP and Head of R&D
• Patricia Borga Suvari,
  Chief Legal Officer & Sec.
• Mark Perry,
  Lead Independent Director
• Scott Morrison,
  Independent Director
• Wendy Yarno,
  Independent Director
• Deval Patrick,
  Director
• Glenn Pierce,
  Independent Director
• Philip Pizzo,
  Independent Director
• Willie Brown,
  Independent Director
• Dawn Svoronos,
  Independent Director
• Eric Fink,
  Chief Human Resource Officer
• Stephanie Yao,
  Sr. Director of Corp. Communications & Investor Relations
• Nazila Habibizad,
  Exec. VP of Operations
• Dr. Andrej Sali Ph.D.,
  Founder & Advisor
• Dr. Matthew P. Jacobson Ph.D.,
  Founder & Advisor
• Dr. David R. Phillips,
  Founder & Advisor
• Lesley Ann Calhoun,
  See Remarks
• Rock Ventures Ii, L.P.Third...,
  
• Rock Ventures Ii, L.P.Third...,
  
• Michael W Bonney,
  Director
• Eleanor Ramos,
  Chief Medical Officer
• Kevin P Starr,
  Director
• Charles J Homcy,
  Director
• Robert I Tepper,
  10% owner
• Rock Ventures Ii, L.P.Starr...,
  
• Hing Sham,
  See Remarks
• Joshua Lehrer Graiwer,
  Chief Medical Officer
• Advisors Llcperceptive Life...,
  
• Peter Radovich,
  See Remarks
• Nazila Habibizad,
  See Remarks
• John Schembri,
  See Remarks
• Rock Ventures Ii, L.P.Third...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Carrie Krehlik,
  Chief Human Resources Officer
• Alexis A. Thompson,
  Director
• Kim Smith Whitley,
  See Remarks